- Abstract
- 1. Introduction
- 2. Methodology
- 2.1. Ligand Structure Preparation
- 2.2. Protein Structure Preparation
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A102137897
Anand Balupuri (Department of Biomedical Science, Colleage of Medicine, Chosun University) ; Pavithra K. Balasubramanian (Chosun University) ; Seung Joo Cho
2016
English
PAK1 ; 4-azaindole ; Cancer ; Docking
405
KCI등재후보
학술저널
161-165(5쪽)
0
0
상세조회0
다운로드목차 (Table of Contents)
참고문헌 (Reference)
1 Z. M. Jaffer, "p21-activated kinases:three more join the Pak" 34 : 713-717, 2002
2 R. Kumar, "p21-activated kinases in cancer" 6 : 459-471, 2006
3 C. C. Ong, "Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells" 108 : 7177-7182, 2011
4 W. Lee, "Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1inhibitors" 26 : 3518-3524, 2016
5 M. Lei, "Structure of PAK1in an Autoinhibited Conformation Reveals a Multistage Activation Switch" 102 : 387-397, 2000
6 "SYBYLx2.1, Tripos International, 1699 South Hanley Road, St. Louis, Missouri, 63144"
7 M. F. Sanner, "Python: a programming language for software integration and development" 17 : 57-61, 1999
8 B. Dummler, "Pak protein kinases and their role in cancer" 28 : 51-63, 2009
9 Anand balupuri, "Exploration of the Binding Mode of Indole Derivatives as Potent HIV-1 Inhibitors Using Molecular Docking Simulations" 기초과학연구원 6 (6): 138-142, 2013
10 Anand Balupuri, "Comparative Molecular Field Analysis of Pyrrolopyrimidines as LRRK2 Kinase Inhibitors" 기초과학연구원 9 (9): 1-9, 2016
1 Z. M. Jaffer, "p21-activated kinases:three more join the Pak" 34 : 713-717, 2002
2 R. Kumar, "p21-activated kinases in cancer" 6 : 459-471, 2006
3 C. C. Ong, "Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells" 108 : 7177-7182, 2011
4 W. Lee, "Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1inhibitors" 26 : 3518-3524, 2016
5 M. Lei, "Structure of PAK1in an Autoinhibited Conformation Reveals a Multistage Activation Switch" 102 : 387-397, 2000
6 "SYBYLx2.1, Tripos International, 1699 South Hanley Road, St. Louis, Missouri, 63144"
7 M. F. Sanner, "Python: a programming language for software integration and development" 17 : 57-61, 1999
8 B. Dummler, "Pak protein kinases and their role in cancer" 28 : 51-63, 2009
9 Anand balupuri, "Exploration of the Binding Mode of Indole Derivatives as Potent HIV-1 Inhibitors Using Molecular Docking Simulations" 기초과학연구원 6 (6): 138-142, 2013
10 Anand Balupuri, "Comparative Molecular Field Analysis of Pyrrolopyrimidines as LRRK2 Kinase Inhibitors" 기초과학연구원 9 (9): 1-9, 2016
11 S. T. Staben, "Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors" 57 : 1033-1045, 2014
12 G. M. Morris, "Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function" 19 : 1639-1662, 1998
13 G. M. Morris, "AutoDock4and AutoDockTools4: Automated docking with selective receptor flexibility" 30 : 2785-2791, 2009
14 Anand Balupuri, "A CoMFA Study of Quinazoline-based Anticancer Agents" 기초과학연구원 8 (8): 214-220, 2015
15 Pavithra K. Balasubramanian, "A CoMFA Study of Phenoxypyridine-Based JNK3 Inhibitors Using Various Partial Charge Schemes" 기초과학연구원 7 (7): 45-49, 2014
16 Anand Balupuri, "A CoMFA Study of Glycogen Synthase Kinase 3 Inhibitors" 기초과학연구원 8 (8): 40-47, 2015
In silico Analysis of Natural Compounds as Modulators of Type I Collagen
Activated Rap1A Induces Osteoblastic Differentiation and Cell Adhesion
Comparative Molecular Similarity Indices Analysis of CXCR-2 Inhibitors
Homology Modelling of Urotension-2 Receptor (UTS2R) : Potential Target for Human Pharmacotherapy
학술지 이력
연월일 | 이력구분 | 이력상세 | 등재구분 |
---|---|---|---|
2022 | 평가예정 | 신규평가 신청대상 (신규평가) | |
2021-12-01 | 평가 | 등재후보 탈락 (계속평가) | |
2020-12-01 | 평가 | 등재후보로 하락 (재인증) | |
2017-01-01 | 평가 | 등재학술지 유지 (계속평가) | |
2013-01-01 | 평가 | 등재학술지 선정 (등재후보2차) | |
2012-01-01 | 평가 | 등재후보 1차 PASS (등재후보1차) | |
2010-01-01 | 평가 | 등재후보학술지 선정 (신규평가) |
학술지 인용정보
기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
---|---|---|---|
2016 | 0.45 | 0.45 | 0.35 |
KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
0.28 | 0.25 | 0.24 | 0.05 |